The DETECT Trial
Protocol ID: The DETECT Trial
Official Title: The Efficacy and Safety of a Single Oral Dose of 1.0MG/KG Macimorelin Acetate as Growth Hormone Stimulation Test (GHST) in Pediatric Patients with Suspected Growth Hormone Deficiency (GHD)
PI Name: Eric Felner, MD
Lead CRC: Amber Antich, CRC II
Condition or Disease: Short Stature
Brief Summary: To determine the diagnostic efficacy of macimorelin in diagnosing suspected GHD in pediatric subjects assuming the outcome of GHD status adjudication by the external adjudication committee as the “true” GHD status.
Study Type/Primary Purpose: Interventional
Study Status: Recruiting
Endocrine Autoimmunity
Protocol ID: Endocrine Autoimmunity
Official Title: Immune Function during Various Stages of Type 1 Diabetes: Autoimmunity, Genetics and Immune Markers
PI Name: Andrew Muir, MD
Lead CRC: Amber Antich, CRC II
Condition or Disease: Healthy Individuals
Brief Summary: To collect and store blood samples on individuals with Type 1 diabetes (T1DM) and Healthy Individuals for genetic and immune testing.
Study Status: Recruiting
Crinecerfont in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
PI Name: Eric Felner, MD
Lead CRC: Lynette Gonzalez, CRC I
Condition or Disease: Classic Congenital Adrenal Hyperplasia
Brief Summary: To evaluate the efficacy of crinecerfont, compared with placebo, in reducing adrenal steroid levels during a glucocorticoid-stable period
Study Type/Primary Purpose: Interventional
Study Status: Recruiting